TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03413371
Drug: 0,5 % bupivacaine with of 2% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in group BL patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
Study: NCT03413371
Drug: 1 % ropivacaine with of 2% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in group RL patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
Study: NCT01257425
Drug: Triptorelin Pamoate (Pamorelin® LA 11.25 mg)
Normalized name: Triptorelin Pamoate
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85.~Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85.
Study: NCT00706680
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: methyl prednisone intravenously pre-operatively, as per institutional practice. Thymoglobulin, initiated prior to completion of the anastomosis, or if not possible, within 24 hours of transplantation for a total dose of 6-7.5mg/kg given over 3-5 doses. Steroids initiated post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day for 2 days. Patients will be placed on 5mg daily for the remainder of the study. All patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.
Study: NCT00513643
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6, 12, 24 U s.c.
Study: NCT01182194
Drug: YAZ®
Normalized name: Drospirenone and ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 mg/0.02 mg Tablets
Study: NCT00307502
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets 200 mg, 400 mg/day
Study: NCT00307502
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets 600 mg, 600 mg/day
Study: NCT00307502
Drug: Indinavir/ritonavir
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indinavir: capsules 400 mg, 1600 mg/day~Ritonavir: capsules 100 mg, 200 mg/day
Study: NCT00307502
Drug: Nelfinavir
Normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets 250 mg, 2500 mg/day
Study: NCT03413371
Drug: 1 % Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in group R patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (5 ml)
Study: NCT00307502
Drug: Saquinavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Saquinavir: tablets 500 mg, 2000 mg/day~Ritonavir: tablets 100 mg, 200 mg/day
Study: NCT00307502
Drug: Lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day
Study: NCT00307502
Drug: Atazanavir
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: capsules 200 mg, 400 mg/day
Study: NCT00307502
Drug: Atazanavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Atazanavir: capsules 150 mg, 300 mg/day~Ritonavir: capsules 100 mg, 200 mg/day
Study: NCT00307502
Drug: Fos-amprenavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fos-amprenavir: capsules 700 mg, 1400 mg/day~Ritonavir: capsules 100 mg, 200 mg/day
Study: NCT00307502
Drug: Tipranavir/ ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tipranavir: tablets 250 mg, 1000 mg/day~Ritonavir: capsules 100 mg, 400 mg/day
Study: NCT00307502
Drug: Darunavir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darunavir: tablets 300 mg, 1200 mg/day~Ritonavir: capsules 100 mg, 200 mg/day
Study: NCT00506987
Drug: SCH 486757
Normalized name: SCH-486757
DrugBank: SCH-486757 (DB12782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 486757 2 x 50-mg capsule twice daily orally for 2 weeks followed by a 2-week washout period and 2 weeks of crossover treatment
Study: NCT03413371
Drug: 0,5 % bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in group B patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
Study: NCT01781507
Drug: Cetirizine
Normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cetirizine is an antihistamine currently indicated for allergic rhinitis
Study: NCT00552487
Drug: synacthen
Normalized name: Synacthen Depot
DrugBank: Tetracosactide (DB01284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 µg synacthen in the vein
Study: NCT03504917
Drug: Balovaptan
Normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 10 mg of oral administration balovaptan once a day (QD).
Study: NCT03629639
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: An intervention of either metformin or placebo 500mg twice daily plus standard care for 12 weeks. Besides Metformin, standardized topical treatment is given to all patients; For severe psoriasis patients(PASI\>8), Methotrexate will be treated orally 7.5mg every week for both the intervention group and the placebo group as a systemic standard care.
Study: NCT05218564
Drug: Oxygen Therapy
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the 6 Minute Walking Test (6MWT), the participant will be required to walk as fast as possible on a flat, straight surface on the ward (e.g. corridor) in six minutes, including as many breaks as he/she deems necessary. The performance of this test will be monitored continuously by a Respiratory Physiotherapist and will include the presence of a Physician, who will be ready to assist as needed. The sequence of use of compressed medical air and oxygen used during the 6MWT in the first group will then be characterised as follows: ABC (A=Baseline, B=Air, C=Oxygen). The sequence of the second group will be characterised as follows: ACB (A=Baseline, B=Air, C=Oxygen).
Study: NCT00971243
Drug: MP-513 Lowest Dose and Metformin
Normalized name: 6 MP
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
Study: NCT00971243
Drug: MP-513 Low Dose and Metformin
Normalized name: 6 MP
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
Study: NCT00971243
Drug: MP-513 Medium Dose and Metformin
Normalized name: 6 MP
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
Study: NCT00971243
Drug: MP-513 High Dose and Metformin
Normalized name: 6 MP
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
Study: NCT02953860
Drug: Fulvestrant with Enzalutamide
Normalized name: Enzalutamide
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.
Study: NCT00642733
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg po daily
Study: NCT00642733
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 iv weekly for 8 weeks, then weekly for 3 weeks of each 4 week cycle
Study: NCT02486744
Drug: Acthar Gel
Normalized name: Acthar Gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be given an injection subcutaneously 2x week for 6 months. Dosing will be randomly assigned as either 80 U or 40 U
Study: NCT03111121
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: receive reversal with sugammadex 4mg/kg
Study: NCT03111121
Drug: neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: receive reversal with neostigmine 0.04 mg/kg
Study: NCT03111121
Drug: glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive reversal with glycopyrrolate (0.01 mg/kg)
Study: NCT04153513
Drug: Lanolin
Normalized name: Lanolin
DrugBank: Lanolin (DB11112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanolin will be applied by hand in a thin layer to the nipple and areola after every breast feed (approximately every 2 to 3 hours) for a maximum of 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
Study: NCT00822523
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single Dose, Intramuscular into right EDB muscle
Study: NCT03573349
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: We will enroll 20 adults (aged 18-65 years) with treatment-resistant depression and will provide two i.v. ketamine infusions (0.5 mg/kg, infused over 40 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers), and following ketamine treatment (change biomarkers). This will be an open-label feasibility trial.
Study: NCT02174042
Drug: Tangning Tongluo Capsule
Normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken drugs 3 times a day, with each time 3 grains
Study: NCT01003678
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.~Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug.
Study: NCT01000285
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01000285
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01000285
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01000285
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01000285
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01300962
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: trastuzumab infusion on day 1 of each cycle.
Study: NCT01300962
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: lapatinib daily for 21 days in each cycle.
Study: NCT00372567
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 37.5 mg daily
Study: NCT00372567
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 800mg daily
Study: NCT01598311
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin hydrochloride 125 mg capsule over-encapsulated in size 00 opaque hard gelatin capsule.
Study: NCT03834038
Drug: Lyophilized Fecal Microbiota Transplantation
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized FMT
Study: NCT04308343
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs to treat undisturbed ectopic pregnancies
Study: NCT04308343
Drug: cetrotide
Normalized name: Cetrotide
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs to treat undisturbed ectopic pregnancies
Study: NCT01372423
Drug: Lubiprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 mcg capsules
Study: NCT02349113
Drug: Estrogens (Climara)
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with estrogens: Estradiol dermal patch 0.1mg/d transdermally
Study: NCT04351737
Drug: Intracanalicular Dexamethasone, (0.4 mg) Insert
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo bilateral pterygium surgery.
Study: NCT03439254
Drug: Obeticholic acid (10 mg)
Normalized name: obeticholic acid 10 MG
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets administered orally once daily.
Study: NCT03439254
Drug: Obeticholic acid (10 mg to 25 mg)
Normalized name: obeticholic acid 10 MG
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets administered orally once daily.
Study: NCT00279422
Drug: visilizumab
Normalized name: Visilizumab
DrugBank: Visilizumab (DB12053)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02334501
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02334501
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00402883
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/kg week 1, 4, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, and 49.
Study: NCT00402883
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg/m2 week 1, 4, 16, 19 and 22.
Study: NCT03531970
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Corticostroide
Study: NCT01304238
Drug: lepirudin
Normalized name: Lepirudin
DrugBank: Lepirudin (DB00001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lepirudin
Study: NCT01304238
Drug: danaparoid
Normalized name: DANAPAROID
DrugBank: Danaparoid (DB06754)
Approvals — FDA: no, EMA: no, PMDA: no
Description: danaparoid
Study: NCT01304238
Drug: argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: argatroban
Study: NCT01304238
Drug: fondaparinux
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fondaparinux
Study: NCT04123574
Drug: Talabostat Mesylate
Normalized name: mesylate
DrugBank: Talabostat (DB06182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BXCL701 tablets dosage strengths include 0.2mg and 0.05mg tablets for oral administration.~Patients are to self-administer the prescribed number of BXCL701 tablets for a total daily dose of 0.6 mg. BXCL701 should not be taken on an empty stomach.~Daily blood pressure monitoring will be performed during the dosing period. Administration of at least 1L of intravenous (IV) fluids is required on Day 1.~On days when pharmacokinetic (PK) assessments are being performed, BXCL701 should be administered at the study center and should be administered at (approximately) the same time of day on each treatment day.
Study: NCT02495389
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron is a medication for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved by the United States Food and Drug Administration (FDA) in July 2012.
Study: NCT03532087
Drug: Denosumab 120 mg
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab 120 mg every 3 weeks.
Study: NCT03532087
Drug: Denosumab 60 mg
Normalized name: denosumab 60 MG/ML
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab 60 mg every 6 months.
Study: NCT00137553
Drug: Sulfadoxine-pyrimethamine (Fansidar)
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01389778
Drug: Metformin ER
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin ER 1500 mg for 12 weeks
Study: NCT01389778
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02136693
Drug: Psyllium fiber
Normalized name: Konsyl Daily Psyllium Fiber
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g /day of pure Psyllium fiber for 180 days after STARR
Study: NCT03730857
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: olanzapine tablet
Study: NCT03730857
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: risperidone tablet
Study: NCT03730857
Drug: Paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: paliperidone tablet
Study: NCT00402883
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=5 administered intravenously weeks 1 and 4.
Study: NCT00824785
Drug: EOX + panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days
Study: NCT00411320
Drug: oral steroid-dexamethasone
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 week steroid trial
Study: NCT02585869
Drug: Gemcabene 150 mg
Normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded capsules and tablets, 150 mg, once daily, 84 days
Study: NCT00036959
Drug: ABT-751
Normalized name: ABT-751
DrugBank: ABT-751 (DB12254)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01703650
Drug: iopromide
Normalized name: Iopromide
DrugBank: Iopromide (DB09156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. iopromide (370mgI/mL) enhanced perfusion CT will be performed within 14 days of operation.~2. In patients who are planned to receive chemotherapy, iopromide enhanced perfusion CT was performed twice; within 14 days before starting 1st cycle and within 14 days after finishing 2nd cycle.~3. iopromide (370mgI/mL) will be administered intravenously with an amount of 30mL (body weight\[BW\] \<50kg) or 35 mL (50kg ≤BW \<70kg) or 40 mL (70 kg≤BW \<90kg) or 50 mL (90≤BW), followed by saline infusion (30mL).~4. Injection rate is as follows; 6.0mL/sec if BW is \<50kg, 7.0 mL/sec if BW is 50kg≤and \<70kg, 8.0 mL/sec if BW is 70≤and\<90kg and 9.0mL/sec if BW is 90kg≤.
Study: NCT02585869
Drug: Gemcabene 300 mg
Normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded capsules and tablets, 300 mg, once daily, 84 days
Study: NCT02585869
Drug: Gemcabene 600 mg
Normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded capsules and tablets, 600 mg, once daily, 84 days
Study: NCT02585869
Drug: Gemcabene 900 mg
Normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinded capsules and tablets, 900 mg, once daily, 84 days
Study: NCT00770406
Drug: botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 100 or 200 units intravesically
Study: NCT02064556
Drug: Amlodipine 10mg
Normalized name: AMLODIPINE 10MG/VALSARTAN 160MG TAB
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 10mg 1T, PO, QD for 9days
Study: NCT02064556
Drug: Amlodipine 10mg/Candesartan 32mg
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
Study: NCT03929744
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT03929744
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally.
Study: NCT03029351
Drug: Exenatide Extended Release for Inj Susp 2 MG
Normalized name: exenatide Injection
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria
Study: NCT03484845
Drug: Lactoferrin and ferrous fumarate
Normalized name: ferrous fumarate and folic acid
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .~* Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .~* Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily .
Study: NCT00661479
Drug: 400 µg Brimonidine Tartrate Implant
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 µg brimonidine tartrate implant in the study eye on Day 1.
Study: NCT00661479
Drug: 200 µg Brimonidine Tartrate Implant
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 µg brimonidine tartrate implant in the study eye on Day 1.